Int J Obes , 2024, DOI: 10.1038/s41366-024-01526-2, Written by Tarun Sai Lomte Tarun is a writer based in Hyderabad, India
Food and Drug Administration (FDA) to improve glycemic control in patients with type 2 diabetes mellitus (T2DM), along with exercise and a balanced diet
Semaglutide disrupts at least three of those conditions
One study showed that low doses can be beneficial for 3-6 month treatments, at which point, 80% of responsive participants experienced normal menstrual cycles
The Endocrine Societys clinical practice guideline on pharmacological management of obesity, published in the Journal of Clinical Endocrinology and Metabolism, outlines the patient criteria under which weight loss medications are medically indicated